Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts
Strategic Applications of Flow Chemistry within Drug Discovery
Paul Richardson, Synthesis Group Leader, Pfizer, speaking at Flow Chemistry Congress.
Date Posted: Tuesday, October 16, 2012
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Merck and Pfizer Finalize Agreement to Co-Promote XALKORI®
Co-promotion of XALKORI allows the alliance between Merck KGaA, Darmstadt, Germany, and Pfizer to establish a combined oncology sales organization in key markets for the program.
Thursday, April 09, 2015
Pfizer to Acquire Hospira for $17B
Companies have into a definitive merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion.
Thursday, February 05, 2015
Pfizer Acquires Redvax
Acquisition provides Pfizer with a preclinical CMV vaccine candidate.
Thursday, January 08, 2015
Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform
Signs collaboration with Spark Therapeutics to advance phase 1/2 Adeno-associated virus (AAV) vector program in hemophilia B.
Friday, December 12, 2014
Pfizer, Merck to Evaluate Novel Anti-Cancer Combination Regimen
This multi-center, open-label clinical study will be conducted by Pfizer and is expected to begin in 2015.
Wednesday, August 27, 2014
Pfizer to Acquire InnoPharma
Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.
Wednesday, July 16, 2014
Pfizer Confirms Interest in AstraZeneca
Pfizer submitted a preliminary, non-binding indication of interest to the board of directors of AZ in January 2014 regarding a possible merger transaction.
Monday, April 28, 2014
Pfizer Announces Plan for Split-Off of Zoetis
The offer better positions Pfizer to focus on its core business as an innovative biopharmaceutical company.
Thursday, May 23, 2013
Pfizer Presents Phase 3 Safety And Immunogenicity Data On HIV Drug
Pfizer Inc. presented the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13® in adults infected with HIV.
Tuesday, March 05, 2013
Pfizer Announces Resolutions with DOJ and SEC Related to Certain International Operations
U.S. agencies praise Company’s cooperation and compliance program.
Thursday, August 09, 2012
Pfizer Announces Positive Results From Phase 3 Cancer Study
Study PROFILE 1007 evaluates XALKORI® (crizotinib) in previously treated patients with ALK-positive advanced non-small cell lung cancer.
Wednesday, June 27, 2012
Pfizer Maneuvers to Protect Lipitor from Generics
Lipitor is so valuable that Pfizer is practically paying people to keep taking its blockbuster cholesterol medicine after generic competition hit the U.S. market last week.
Tuesday, December 06, 2011
Pfizer to Acquire Icagen
Pfizer Inc. and Icagen, Inc. announce that they have entered into a definitive merger agreement.
Thursday, August 04, 2011
Pfizer and Samsung Medical Center Collaborate on Liver Cancer
Collaboration aims to conduct joint research to identify genomic mechanisms responsible for clinical outcomes in hepatocellular carcinoma.
Friday, July 16, 2010
Pfizer Joins Open-Access Medicinal Chemistry Public-Private Collaboration
Company joins the SGC-led public-private collaboration to generate small molecule inhibitors for proteins involved in epigenetic signalling.
Tuesday, June 15, 2010
Scientific News
NIH-funded Study Points Way Forward for Retinal Disease Gene Therapy
Benefits for Leber congenital amaurosis peak after one to three years, then diminish.
Study Points to Possible Treatment for Lethal Pediatric Brain Cancer
NIH-funded preclinical study suggests epigenetic drugs may be used to treat leading cause of pediatric brain cancer death.
Mutations in Two Genes Linked to Familial Pulmonary Fibrosis and Telomere Shortening
PARN and RTEL1 genes strengthen the link between lung fibrosis and telomere dysfunction.
New Research Into Health Benefits Of Coffee
New research has brought us closer to being able to understand the health benefits of coffee.
Progress Towards A New Asthma Treatment
University of Queensland researchers are developing a new asthma treatment that targets the underlying cause of asthma, rather than just the symptoms.
Multiple Types Of Resistance To New Lung Cancer Drug Identified
Study shows genomic heterogeneity in mechanisms of resistance to TKI drugs.
Compound To Combat Malaria Parasite Identified
Study identifies non-mevalonate pathway for isoprenoid biosynthesis as key antimalarial drug target.
Proteomics Identifies DNA Repair Toolbox
Max-Planck scientists identify protein profiles of DNA repair.
Diet Swap has Dramatic Effects on Colon Cancer Risk for Americans and Africans
New study confirms that a high fibre diet can substantially reduce risk.
Statement on NIH Funding of Research Using Gene-Editing Technologies in Human Embryos
Researchers modify the gene responsible for a potentially fatal blood disorder using CRISPR/Cas9 technology.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters